Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection

Journal of Antimicrobial Chemotherapy

Volumn 38, Issue 4, 1996, Pages 691-699

  Tumbarello, Mario ^a   Caldarola, Germana ^b   Tacconelli, Evelina ^b   Morace, Giulia ^a   Posteraro, Brunella ^a   Cauda, Roberto ^b   Ortona, Luigi ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b Univ̀ Cattolica Sacro Cuore ^*

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE;

ADULT; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA TROPICALIS; CANDIDIASIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; RISK FACTOR; YARROWIA LIPOLYTICA;

EID: 0029822361     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/38.4.691     Document Type: Article

References (28)

1. Baily, G. G., Perry, F. M., Denning, D. W. & Mandal, B. K. (1994). Fluconazole resistant candidosis in an HIV cohort. AIDS 8, 787-92.
2. Barchiesi, F., Hollis, R. J., McGough, D. A., Scalise, G., Rinaldi, M. G. & Pfaller, M. A. (1995). DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS. Clinical Infectious Diseases 20, 634-40.
3. Bennett, J. E. (1990). Antimicrobial agents: antifungal agents. In Goodman and Gilman's the Pharmacological Basis of Therapeutics, 8th edn (Gilman, A. G., Rall, T. W., Nies, A. S., Taylor, P. Eds), pp. 1165-181. Pergamon Press, New York.
4. Boken, D. J., Swindells, S. & Rinaldi, M G. (1993). Fluconazole resistant Candida albicans. Clinical Infectious Diseases 17, 1018-21.
5. Center for Diseases Control (1992). 1993 revised classification systems for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report 41-47.
6. Chavanet, P., Lopez, J., Grappin, M., Boumin, A., Duong, M., Waldmin, A. et al. (1994). Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV infected patients. AIDS 8, 945-50.
7. Dios, P. D., Hermida, A. O., Alvarez, C. M., Martin, I. & Varela, O. (1995). Fluconazole-resistant oral candidiasis in HIV infected patients. AIDS 9, 808-24.
8. Diz, P., Ocampo, A., Miralles, C., Otero, I., Iglesias, I. & Martinez, C. (1993). Oroesophageal candidosis resistant to fluconazole in patients with AIDS. European Infectious Microbiological Clinics 11, 36-9.
9. Epstein, J. B., Pearsall, N. N. & Truelove, E. L. (1980). Quantitative relationships between Candida albicans in saliva and the clinical status of human subjects. Journal of Clinical Microbiology 12, 475-76.
10. Espinel-Ingroff, A. & Pfaller, M. A. (1995). Antifungal agent's and susceptibility testing. In Manual of Clinical Microbiology, 6th edn (Murray, P. R., Baron, E. J., Pfaller, M. A., Tenover, F. C. & Yolken, R. H., Eds), pp. 1405-14. American Society for Microbiology, Washington, DC.
11. Feigal, D. W., Katz, M. H., Greenspan, D., Westenhouse, J., Winkelstein, W., Leng, W. et al. (1991). The prevalence of oral lesions in HIV infected homosexual and bisexual men: three San Francisco epidemiological cohorts. AIDS 5, 519-25.
12. Grant, S. M. & Clissold, S. P. (1989). Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37, 310-44.
13. Hughes, C. E., Bennett, R. L., Tuna, I. C. & Beggs, W. H. (1988). Activities of fluconazole (UK 40,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans. Antimicrobial Agents and Chemotherapy 32, 209-12.
14. Johnson, E. M., Warnock, D. W., Porter, S. R. & Scully, C. (1995). Emergence of azole drug resistance in Candida species from HIV infected patients receiving prolonged fluconazole therapy for oral candidosis. Journal of Antimicrobial Chemotherapy 35, 103-114.
15. Meunier, F., Aoun, M. & Gerard, M. (1990). Therapy for oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs. ketoconazole. Review of Infectious Diseases 12, S364-8.
16. Morace, G., Manzara, S. & Dettori, G. (1991). In vitro susceptibility of 119 yeast isolates to fluconazole, 5 fluorocytosine, amphotericin B and ketoconazole. Chemotherapy 37, 23-31.
17. Morace, G., Sanguinetti, M., Posteraro, B. & Pagano, L. (1995). In vitro susceptibility of Candida species from patients with haematological malignancies. Mycoses 38, 59-67.
18. Ng, T. T. C. & Denning, D. W. (1993). Fluconazole resistance in Candida in patients with AIDS - therapeutic approach. Journal of Infection 26, 117-25.
19. Polis, S. A. & Kovacs, J. A. (1992). Fungal infections in patients with the acquired immunodeficiency syndrome. In AIDS: etiology, diagnosis, treatment and prevention, 3rd edn (De Vita, V. T., Hellmam, S. & Rosemberg, S. A., Eds), pp. 167-80. J. B. Lippincott, Philadelphia.
20. Polonelli, L. & Morace, G. (1984). A microautomated dilution method for susceptibility testing with antifungal drugs. Mycopathologia 86, 21-8.
21. Redding, S., Smith, J., Farinacci, G., Rinaldi, M., Foolergill, A., Rhine-Chálberg, J. (1994). Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clinical Infectious Diseases 18, 240-42.
22. Rex, J. H., Rinaldi, M. G. & Pfaller, M. A. (1995). Resistance of Candida species to fluconazole. Antimicrobial Agents and Chemotherapy 39, 1-8.
23. Rogers, T. R. F., and members of the British Society for Antimicrobial Chemotherapy Working Party. (1992). Antifungal chemotherapy in patients with the acquired immunodeficiency syndrome. Lancet 340, 648-51.
24. Rothenberg, R., Woeffel, M., Stoneburner, R., Milberg, J., Parker, R., Truman, B. (1987). Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York city. New York Journal of Medicine 317, 1297-302.
25. Sargeorzan, J. A., Bradley, S. F., He, X., Zaxi ms, L. T., Riolenour G. L., Tibelli, R. V. (1994). Epidemiology of oral candidiasis in HIV infected patients: colonisation, infection, treatment and emergence of fluconazole resistance. American Journal of Medicine 97, 339-46.
26. Spencer, P. M. & Jackson, G. G. (1989). Fungal and mycobacterial infections in patients infected with the Human Immunodeficiency Virus. Journal of Antimicrobial and Chemotherapy 23, 107-25.
27. Whimbey, E., Gold, J. W. M., Polsky, B., Dryjenski, J., Hawkkins, C., Blevins, A. (1986). Bacteremia and fungemia in patients with the acquired immunodeficiency syndrome. Annals of Internal Medicine 104, 511-14.
28. Wood, A. J. J. (1994). Oral azole drugs as systemic antifungal therapy. New England Journal of Medicine 330, 263-72.